- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: System justification.
Displaying page 1 of 1.
EudraCT Number: 2020-004084-10 | Sponsor Protocol Number: T001018N | Start Date*: 2022-05-16 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Flemisch Fund for Scientific Research - Fonds voor Wetenschappelijk Onderzoek | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment; a pragmatic randomised controlled trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Rifampicin resistant (RR-TB) and drug resistant (DR-TB) tuberculosis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006444-19 | Sponsor Protocol Number: AX200-101 | Start Date*: 2009-05-12 | |||||||||||
Sponsor Name:SYGNIS Bioscience GmbH & Co. KG | |||||||||||||
Full Title: AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial | |||||||||||||
Medical condition: ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) SE (Prematurely Ended) PL (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004898-41 | Sponsor Protocol Number: NBK241/1/2020 | Start Date*: 2021-03-31 | |||||||||||
Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
Full Title: A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissu... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001240-61 | Sponsor Protocol Number: allo-APZ2-ACLF-II-01 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:RHEACELL GmbH & Co. KG | |||||||||||||
Full Title: An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF) | |||||||||||||
Medical condition: Acute-on-Chronic Liver Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005504-18 | Sponsor Protocol Number: APHP201185 | Start Date*: 2021-05-21 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by ablative procedure in a curative intent: multicentre phase 2 therapeutic trial | ||
Medical condition: NA | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001807-19 | Sponsor Protocol Number: TV50717-CNS-30081 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) | |||||||||||||
Medical condition: Dyskinesia in cerebral palsy (DCP) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005611-31 | Sponsor Protocol Number: CORT113176-652 | Start Date*: 2022-09-07 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004460-19 | Sponsor Protocol Number: P1604GTN | Start Date*: 2017-04-20 | |||||||||||
Sponsor Name:G. Pohl-Boskamp GmbH & Co.KG | |||||||||||||
Full Title: A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in... | |||||||||||||
Medical condition: Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002320-33 | Sponsor Protocol Number: GRC17536-203 | Start Date*: 2012-09-27 | |||||||||||
Sponsor Name:Glenmark Pharmaceuticals SA | |||||||||||||
Full Title: A Phase 2, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Pe... | |||||||||||||
Medical condition: Pain associated with diabetic peripheral neuropathy (DPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001419-64 | Sponsor Protocol Number: NOR-107 | Start Date*: 2014-01-24 | |||||||||||
Sponsor Name:Takeda Vaccines (Montana), Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv... | |||||||||||||
Medical condition: Prevention of gastroenteritis caused by norovirus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001379-21 | Sponsor Protocol Number: VX15-770-126 | Start Date*: 2017-08-01 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000931-35 | Sponsor Protocol Number: D6470C00005 | Start Date*: 2020-10-05 | |||||||||||
Sponsor Name:AstraZeneca AB, 151 85 Södertälje, Sweden | |||||||||||||
Full Title: A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000127-32 | Sponsor Protocol Number: ROPETAR | Start Date*: 2011-11-03 | |||||||||||||||||||||
Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie | |||||||||||||||||||||||
Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin... | |||||||||||||||||||||||
Medical condition: Advanced or metastatic clear cell renal cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006441-10 | Sponsor Protocol Number: 116-02 | Start Date*: 2009-06-03 |
Sponsor Name:SCIPHARM SáRL | ||
Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper... | ||
Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-005879-16 | Sponsor Protocol Number: GRC17536-201 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:Glenmark Pharmaceuticals SA | |||||||||||||
Full Title: A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic N... | |||||||||||||
Medical condition: Pain associated with diabetic peripheral neuropathy (DPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003697-10 | Sponsor Protocol Number: 109MS302 | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IE (Completed) GR (Completed) EE (Completed) LV (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004805-30 | Sponsor Protocol Number: CLN-PXT3003-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pharnext SCA | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) | |||||||||||||
Medical condition: Charcot Marie Tooth Type 1A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
